Joinn Laboratories (SHA:603127, HKG:6127) said its recent stock rally could have been triggered by its half-year earnings guidance, according to a Friday filing with the Shanghai bourse.
The drug research company's closing price deviated by more than 20% across three straight trading sessions from July 14 to 16.
Joinn Lab expects its attributable profit to surge 885% to 1,377% to between 600.1 million yuan and 900.2 million yuan for the first half.
Shares fell 7% in Hong Kong during late afternoon trading, and closed 10% in Shanghai on Friday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments